April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

Beijing antibody play Mabworks raises $160M
Mabworks Biotech Co. Ltd. raised RMB1.1 billion ($160 million) in series C1 and C2 rounds to support development and commercialization of its antibody pipeline for various cancers, autoimmune, metabolic and infectious diseases. The round was co-led by CICC Qide Fund, Lyzz Capital, CITIC Securities Investment and

Read the full 512 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE